EZH2 and cancer: Some of the molecules that have been already developed such as the small-molecule inhibitors of PRC2 or EZH2 are actually under clinical evaluation for the treatment of some kinds of cancers including germinal-center B-cell lymphomas characterized by EZH2 mutations, which represent about 15–20% of all cases.